GWM
ARQT icon

Geneos Wealth Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Geneos Wealth Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-460
Closed -$9K – 2030
2022
Q2 		$9K Hold
460
– – ﹤0.01% 1971
2022
Q1 		$8K Hold
460
– – ﹤0.01% 2158
2021
Q4 		$9K Hold
460
– – ﹤0.01% 2203
2021
Q3 		$11K Buy
+460
New +$10.5K ﹤0.01% 2170

Other funds holding ARQT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geneos Wealth Management's ARQT Position: Q3 2022 in Review

Geneos Wealth Management sold out of Arcutis Biotherapeutics (ARQT) in Q3 2022, closing a stake of 460 shares — an estimated $9K sold.

Geneos Wealth Management first reported a position in ARQT in Q3 2021 and held it in 4 quarters. The position peaked at $11K in Q3 2021. 139 funds tracked by Wall St. Rank hold ARQT as of Q3 2022.

  • Geneos Wealth Management reported no remaining Arcutis Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Geneos Wealth Management sold 460 Arcutis Biotherapeutics shares in Q3 2022, an estimated $9K.
  • Geneos Wealth Management first reported a position in Arcutis Biotherapeutics in Q3 2021 and held it in 4 quarters.
  • Geneos Wealth Management's Arcutis Biotherapeutics position peaked at $11K in Q3 2021.
  • 139 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2022.

Based on Geneos Wealth Management's 13F filing for Q3 2022, filed 14 Nov 2022.